These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 31558782)
1. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies. Lawson NL; Dix CI; Scorer PW; Stubbs CJ; Wong E; Hutchinson L; McCall EJ; Schimpl M; DeVries E; Walker J; Williams GH; Hunt J; Barker C Mod Pathol; 2020 Apr; 33(4):518-530. PubMed ID: 31558782 [TBL] [Abstract][Full Text] [Related]
2. Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies With Different Binding Epitopes: Comparison of 7 Clones. Lawson NL; Scorer PW; Williams GH; Vandenberghe ME; Ratcliffe MJ; Barker C Mod Pathol; 2023 Sep; 36(9):100220. PubMed ID: 37230414 [TBL] [Abstract][Full Text] [Related]
3. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348 [TBL] [Abstract][Full Text] [Related]
4. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609 [TBL] [Abstract][Full Text] [Related]
5. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N. Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072 [TBL] [Abstract][Full Text] [Related]
6. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. Zajac M; Scott M; Ratcliffe M; Scorer P; Barker C; Al-Masri H; Rebelatto MC; Walker J Diagn Pathol; 2019 Sep; 14(1):99. PubMed ID: 31477145 [TBL] [Abstract][Full Text] [Related]
7. PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study. Paliogiannis P; Lobrano R; Bella MA; Fara A; Uras MG; Pinna MA; Tedde A; Madonia M; Zinellu A; Cossu A Ann Diagn Pathol; 2024 Apr; 69():152267. PubMed ID: 38266544 [TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N). Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584 [TBL] [Abstract][Full Text] [Related]
9. Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma. Naso JR; Wang G; Banyi N; Derakhshan F; Shokoohi A; Ho C; Zhou C; Ionescu DN Ann Diagn Pathol; 2021 Feb; 50():151590. PubMed ID: 33157383 [TBL] [Abstract][Full Text] [Related]
10. Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC). Wang X; He J; Li J; Wu C; Yue M; Niu S; Jia Y; Jia Z; Cai L; Liu Y J Cancer Res Clin Oncol; 2024 Jan; 150(2):43. PubMed ID: 38280970 [TBL] [Abstract][Full Text] [Related]
11. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808 [TBL] [Abstract][Full Text] [Related]
12. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Adam J; Le Stang N; Rouquette I; Cazes A; Badoual C; Pinot-Roussel H; Tixier L; Danel C; Damiola F; Damotte D; Penault-Llorca F; Lantuéjoul S Ann Oncol; 2018 Apr; 29(4):953-958. PubMed ID: 29351573 [TBL] [Abstract][Full Text] [Related]
13. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Parra ER; Villalobos P; Mino B; Rodriguez-Canales J Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380 [TBL] [Abstract][Full Text] [Related]
15. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400 [TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays. Dabbagh TZ; Sughayer MA Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):462-466. PubMed ID: 33480602 [TBL] [Abstract][Full Text] [Related]
17. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores. Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450 [TBL] [Abstract][Full Text] [Related]
18. SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3. Pang JB; Castles B; Byrne DJ; Button P; Hendry S; Lakhani SR; Sivasubramaniam V; Cooper WA; Armes J; Millar EKA; Raymond W; Roberts-Thomson S; Kumar B; Burr M; Selinger C; Harvey K; Chan C; Beith J; Clouston D; O'Toole SA; Fox SB; Am J Surg Pathol; 2021 Aug; 45(8):1108-1117. PubMed ID: 34232604 [TBL] [Abstract][Full Text] [Related]
19. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. Maule JG; Clinton LK; Graf RP; Xiao J; Oxnard GR; Ross JS; Huang RSP J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302564 [TBL] [Abstract][Full Text] [Related]
20. A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer. Noske A; Ammann JU; Wagner DC; Denkert C; Lebeau A; Sinn P; Kreipe HH; Sommer U; Baretton G; Steiger K; Kiechle M; Hieke-Schulz S; Flores M; Roth W; Weichert W Histopathology; 2021 Mar; 78(4):567-577. PubMed ID: 32936950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]